Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00103649
Other study ID # EFC2946
Secondary ID SR57746
Status Completed
Phase Phase 3
First received February 11, 2005
Last updated August 20, 2008
Start date November 2003
Est. completion date October 2007

Study information

Verified date August 2008
Source Sanofi
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess xaliproden's potential capacity of slowing the deterioration of cognitive and global functions in patients with mild to moderate Alzheimer's disease. The patients participating in this study will take orally once daily xaliproden or placebo (inactive substance pill).


Recruitment information / eligibility

Status Completed
Enrollment 1306
Est. completion date October 2007
Est. primary completion date October 2007
Accepts healthy volunteers No
Gender Both
Age group 50 Years and older
Eligibility Inclusion Criteria:

- Diagnosis of probable Alzheimer's disease using NINCDS-ADRDA criteria

- Mild to moderate degree of severity of dementia as assessed by the Mini-Mental State Examination score of 16 to 26 (inclusive)

- Potential participant may be treated with conventional Alzheimer's disease therapy and must be on stable dose for at least 6 months prior to the randomization and during the entire study period

- Potential participant must have a reliable caregiver and must be living in a community or in an assisted living facility

- Mother tongue is English, Spanish or French (oral and written fluency)

- Signed informed consent from potential participant or legal representative and identified caregiver

Exclusion Criteria:

- Potential participant with any other cause of dementia.

- Potential participant with serious health problems other than Alzheimer's disease

- Use of an investigational drug within two months prior to randomization or during this study

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
xaliproden (SR57746A)


Locations

Country Name City State
Canada Glenrose Rehabilitation Hospital Edmonton, Alberta
Canada NeuroSearch Developments Inc Greenfield Park Quebec
Canada St. Joseph's Healthcare Hamilton Hamilton, Ontario
Canada Kingston General Hospital Kingston Ontario
Canada Parkwood Hospital - Geriatric Medicine London Ontario
Canada St. Joseph's Health Care London Ontario
Canada Davidson Memory Clinic Moncton, New Brunswick
Canada Hopital Maisonneuve-Rosemont Montreal Quebec
Canada Sir Mortimer B. Davis Jewish General Hospital Montreal Quebec
Canada Parkinson's & Neurodegenerative Disorders Ottawa Ontario
Canada S.C.O. Health Centre Ottawa, Ontario
Canada Medical Arts Health Research Group Penticton British Columbia
Canada Centre de Hospitalier Affilie Quebec
Canada Quebec Memory & Motor Skills Disorders Quebec City Quebec
Canada Pasqua Hospital Regina Saskatchewan
Canada St. Joseph's Hospital Saint John, New Brunswick
Canada Institut Universitaire de Geriatrie de Sherbrooke Sherbrooke Quebec
Canada University Health Network - The Toronto Toronto Ontario
Canada Toronto Memory Program Toronto, Ontario
Canada Douglas Hospital Research Centre Verdun Quebec
Canada Can-Med Clinical Research Inc. Victoria British Columbia
Canada Winnipeg Clinic Winnipeg Manitoba
Canada Winnipeg Clinic Winnipeg, Manitoba
United States DayStar Clinical Research, Inc. Akron Ohio
United States Neurological Association of Albany P.C. Albany New York
United States Lovelace Scientific Resources Albuquerque New Mexico
United States Anaheim Research Center Anaheim California
United States North East Ohio Health Services Beachwood Ohio
United States The Memory Clinic Bennington, Vermont
United States UAB Memory Disorders Clinic Birmingham Alabama
United States Social Psychiatry Research Institute Brooklyn, New York
United States Valley Medical Primary Care Centerville Ohio
United States Charlottesville Medical Research Charlottesville Virginia
United States Chicago Center for Clinical Research Chicago Illinois
United States Coatesville VA Medical Center Coatesville Pennsylvania
United States Remington-Davis Clinical Research Columbus Ohio
United States University of Texas - Southwestern Medical Center at Dallas Dallas, Texas
United States Associated Neurologist Danbury, Connecticut
United States Atlantic Institute of Clinical Research Daytona Beach Florida
United States Radiant Research Denver Colorado
United States Ruan Neurology Des Moines Iowa
United States Duke University Medical Center (DUMC) - Dept. of Psychiatry Durham North Carolina
United States RI Mood and Memory East Providence Rhode Island
United States Elkhart Clinic, LLC Elkhart, Indiana
United States Radiant Research Eugene Eugene Oregon
United States Triphase Research, Ltd. Franklin Ohio
United States TriPhase Research Franklin, Ohio
United States Margolin Brain Institute Fresno California
United States Clinical Insights Glen Burnie Maryland
United States Geriatric and Adult Psychiatry, LLC Hamden Connecticut
United States Berma Research Group Hialeah Florida
United States Radiant Research Center Hoffman Estates Illinois
United States AD Research Center Houston Texas
United States Houston Sleep Center Houston Texas
United States Parker Jewish Institute for Healthcare and Rehabilitation Hyde Park, New York
United States ClinSearch, Inc. Kenilworth, New Jersey
United States Coordinated Clinical Research La Jolla California
United States Senior Clinical Trials, Inc. Laguna Hills California
United States Radiant Research Las Vegas Nevada
United States Neurobehavioral Research, Inc. Lawrence New York
United States Radiant Research Marietta Georgia
United States Clinical Research Institute of Southern Oregon Medford Oregon
United States CNS Healthcare Memphis Tennessee
United States Baumel-Eisner Neuromedical Institute Miami Florida
United States Baumel-Eisner Neuromedical Institute in Miami Beach Miami Florida
United States Miami Research Associates Miami Florida
United States Dean Foundation Middleton Wisconsin
United States Medical College of Wisconsin Milwaukee Wisconsin
United States Minneapolis VA Medical Center Minneapolis Minnesota
United States MedARK Clinical Research Morganton North Carolina
United States The Neuroscience Center of Northern New Jersey Morristown New Jersey
United States Anchor Research Center Naples Florida
United States Vanderbilt University Medical Center - Geriatric Psychiatry Nashville Tennessee
United States Yale University School of Medicine AD Research Unit New Haven Connecticut
United States Louisiana Research Associates New Orleans Louisiana
United States Behavioral Medical Research of Staten Island New York New York
United States Eastside Comprehensive Medical Center New York New York
United States Healthcore Newark Delaware
United States Pharmacology Research Institute Newport Beach California
United States Pearl Clinical Research Norristown Pennsylvania
United States Segal Institute for Clinical Research North Miami Florida
United States Pharmacology Research Institute Northridge California
United States Summit Research Network Michigan, Inc. Okemos Michigan
United States Global Research and Consulting Olean New York
United States Clinical Neuroscience Solutions Orlando Florida
United States Four Rivers Clinical Research Paducah Kentucky
United States Palm Beach Neurological Center Palm Beach Gardens, Florida
United States Memorial Hospital of Rhode Island Pawtucket Rhode Island
United States Memory Disorders Clinic Philadelphia Pennsylvania
United States Radiant Research Philadelphia Pennsylvania
United States Barrow Neurology Clinics Phoenix Arizona
United States PsyPharma Clinical Research, Inc. Phoenix Arizona
United States Clinical Trials Research Services Pittsburgh Pennsylvania
United States JRMC Clinical Trials Center Pittsburgh Pennsylvania
United States Neurology Clinical Research, Inc. Plantation Florida
United States Summit Research Network Inc Portland Oregon
United States Princeton Medical Institute Princeton, New Jersey
United States Neurology Group of Bergen County Ridgewood New Jersey
United States Pharmacology Research Institute Riverside California
United States Pivotal Research Centers, Detroit Office Royal Oak, Michigan
United States Radiant Research SLC Salt Lake City Utah
United States Innovative Clinical Trials San Antonio Texas
United States Pacific Research Network San Diego, California
United States Radiant Research Scottsdale Arizona
United States California Neuroscience Research Medical Group Sherman Oaks California
United States J. Gary Booker MD Shreveport, Louisiana
United States Avera Research Institute Sioux Falls South Dakota
United States Southeastern Geriatric Healthcare Snellville Georgia
United States CNS Clinical Trials St Petersburg Florida
United States Internal Medicine Northwest Tacoma Washington
United States Baumel-Eisner Neuromedical Institute in Miami Beach Tamarac Florida
United States Meridien Research Tampa Florida
United States Suncoast Gerontology Center USF Tampa Florida
United States Neurology and Neuroscience Center of Ohio Toledo Ohio
United States Pacific Research Network Vista, California
United States IPC Research Waukesha Wisconsin
United States Wenatchee Valley Medical Center Wenatchee Washington
United States North Texas Neurology Research Wichita Falls Texas
United States Neurology Associates, PA Wilmington Delaware
United States Piedmont Medical Research Assoc, Inc. Winston-Salem North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Sanofi

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Alzheimer's Disease assessment scale-cognitive, clinical dementia rating sum of boxes.
Secondary Mini-Mental State Examination, Alzheimer's Disease assessment scale-activities of daily life.
See also
  Status Clinical Trial Phase
Completed NCT04044495 - Sleep, Rhythms and Risk of Alzheimer's Disease N/A
Completed NCT04079803 - PTI-125 for Mild-to-moderate Alzheimer's Disease Patients Phase 2
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT04520698 - Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease N/A
Active, not recruiting NCT04606420 - Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease N/A
Recruiting NCT05820919 - Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase N/A
Terminated NCT03672474 - REGEnLIFE RGn530 - Feasibility Pilot N/A
Completed NCT03430648 - Is Tau Protein Linked to Mobility Function?
Recruiting NCT04522739 - Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease Phase 4
Recruiting NCT05288842 - Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
Recruiting NCT04949750 - Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease N/A
Recruiting NCT05557409 - A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation Phase 3
Completed NCT06194552 - A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07 Phase 1
Completed NCT03239561 - Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants Early Phase 1
Completed NCT03184467 - Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients Phase 2
Active, not recruiting NCT03676881 - Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
Terminated NCT03487380 - Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease N/A
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Recruiting NCT05328115 - A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease Phase 1
Completed NCT05562583 - SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support N/A

External Links